非那雄胺后综合症-它真的存在吗?

PubMed ID
发表日期 2019年Dec月

原始出处 老年男性:国际老年男性研究学会的官方刊物
The aging male : the official journal of the International Society for the Study of the Aging Male
作者 Maksym  Radosław B  Kajdy  Anna  Rabijewski  Michał 

文献标题 非那雄胺后综合症-它真的存在吗?
Post-finasteride syndrome - does it really exist?

文献摘要

5α-甾体还原酶抑制剂是治疗雄激素依赖性疾病的药物,包括前列腺疾病和雄激素性脱发。非那雄胺是第一个上市的抑制剂,也是目前应用最广泛的抑制剂。度他列特是第二个被批准的抑制剂,具有类似的安全性。常见的治疗不良事件包括性障碍和负面影响平衡。据报道,脱发患者长期使用5α-甾体还原酶抑制剂可引起持续的副作用,称为非那雄胺后综合征(PFS),这不仅仅是一种简单的事件共存,而是一种具有医源性背景的明确综合征。PFS发生在易感个体中,即使在小剂量的药物后,也会在停止治疗后持续很长时间。受影响个体生活质量的恶化并不能成为使用该药物的理由。对PFS症状、发病率、病程、预防和治疗可能性的更广泛的认识,将使用药适应症得到重新考虑,治疗更加个性化。了解PFS也有助于为受影响的个体提供最佳治疗,并在获得5α-类固醇还原酶抑制剂治疗的知情同意之前对患者进行适当的教育。


Inhibitors of 5α-steroid reductase are drugs used to treat androgen-dependent conditions including prostate diseases and androgenic alopecia. Finasteride was the first on the market and is currently the most widely used inhibitor. Dutasteride was the second inhibitor to be approved and has a similar safety profile. Common adverse events of treatment consist of sexual disorders and a negative affect balance. It was described that the prolonged use of 5α-steroid reductase inhibitors in patients with alopecia can cause persistent side effects called a post-finasteride syndrome (PFS), that is not just a simple coexistence of events, but rather a definite syndrome with an iatrogenic background. PFS occurs in susceptible individuals even after small doses of the drug and can last for a long time after the discontinuation of treatment. A deterioration in the quality of life in affected individuals does not justify use of the drug. Wider recognition of PFS symptoms, its incidence, course, prevention, and treatment possibilities will allow the indications for drug use to be reconsidered and treatment to be more personalized. Knowledge about PFS will also help to provide the best treatment for affected individuals and to properly educate patients before obtaining an informed consent for therapy with 5α-steroid reductase inhibitors.


获取全文 10.1080/13685538.2018.1548589